Zega Financial LLC Has $972,000 Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Zega Financial LLC boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 18.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,184 shares of the medical equipment provider’s stock after buying an additional 347 shares during the quarter. Zega Financial LLC’s holdings in Intuitive Surgical were worth $972,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of ISRG. Gilbert & Cook Inc. lifted its position in shares of Intuitive Surgical by 6.5% in the fourth quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock worth $1,160,000 after purchasing an additional 211 shares in the last quarter. TrinityPoint Wealth LLC lifted its position in Intuitive Surgical by 21.5% during the 4th quarter. TrinityPoint Wealth LLC now owns 1,081 shares of the medical equipment provider’s stock worth $365,000 after buying an additional 191 shares in the last quarter. Hillsdale Investment Management Inc. boosted its stake in shares of Intuitive Surgical by 80.6% during the 4th quarter. Hillsdale Investment Management Inc. now owns 280 shares of the medical equipment provider’s stock worth $94,000 after buying an additional 125 shares during the last quarter. Gladstone Institutional Advisory LLC grew its holdings in shares of Intuitive Surgical by 56.5% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 4,344 shares of the medical equipment provider’s stock valued at $1,465,000 after acquiring an additional 1,569 shares in the last quarter. Finally, Balentine LLC increased its position in shares of Intuitive Surgical by 22.8% in the fourth quarter. Balentine LLC now owns 2,663 shares of the medical equipment provider’s stock valued at $898,000 after acquiring an additional 495 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Robert Desantis sold 1,413 shares of the business’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $438.60, for a total transaction of $619,741.80. Following the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,414,931.60. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock worth $25,528,753 over the last three months. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of analyst reports. Stifel Nicolaus raised their price target on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Evercore ISI decreased their target price on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research note on Friday, July 19th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Barclays increased their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Finally, Morgan Stanley boosted their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Stock Performance

ISRG opened at $483.32 on Wednesday. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18. The company has a market capitalization of $171.43 billion, a P/E ratio of 87.24, a P/E/G ratio of 5.41 and a beta of 1.39. The stock has a fifty day moving average of $465.50 and a 200-day moving average of $423.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the previous year, the firm posted $1.18 EPS. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.